Drugdiscovery >> Drugs >> News
5030
Views
Novartis AG drug might be a blockbuster - late stage test proved - drugdiscovery.com
Novartis AG drug might be a blockbuster - late stage test proved - drugdiscovery.com


Jakavi, ruxolitinib drug of Novartis has produced nice results in patients with myelofibrosis. Patients with at least years of treatment said that their life quality improved significantly.
Read More >>


Tags: Novartis, myelofibrosis, Jakavi, late-stage - March 9, 2014
Related Articles
3105
Views
Raising of a new antidepressant blockbuster Raising of a new antidepressant blockbuster
Lundbeck/Takeda Pharmaceutical's drug Brintellix (vortioxetine) is expected to be among the most successful new agents in the unipolar depression markets by 2022. Read More >>

Tags: antidepressant, blockbuster, Brintellix, vortioxetine, Lundbeck, Takeda

6293
Views
Cancer muscle wasting drug fails in late stage clinical trial Cancer muscle wasting drug fails in late stage clinical trial
GTx ‘drug enobosarm is designed to prevent or treat muscle wasting in cancer patients. Currently, there are no drugs approved for treatment of this condition. In a late-stage clinical trial in patie Read More >>

Tags: muscle wasting, drug, cancer, enobosarm, GTx, cancer cachexia

5559
Views
Gilotrif Approved for Late-Stage Lung Cancer Gilotrif Approved for Late-Stage Lung Cancer
The U.S. Food and Drug Administration approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth Read More >>

Tags: Gilotrif, metastatic non-small cell lung cancer

8406
Views
Novartis muscle drug gets breakthrough therapy designation Novartis muscle drug gets breakthrough therapy designation
The FDA granted a breakthrough therapy status to Novartis’ newly developed compound- bimagrumab (BYM338), used to treat a life-threatening muscle disease called sporadic inclusion body myositis tha Read More >>

Tags: Novartis, cancer cachexia,sarcopenia, COPD, bimagrumab, BYM338, sporadic inclusion body myositis, muscles, waste away

7074
Views
The most promising drugs in biopharma's  late-stage pipeline The most promising drugs in biopharma's late-stage pipeline
An expert’s opinion on which are the 10 most prospective drugs in the late-stage pipeline at this moment. Read More >>

Tags: top 10, most promising, drugs, prospective, biopharma, pipeline

4554
Views
Novartis meningococcal B vaccine - Bexsero approved in Australia Novartis meningococcal B vaccine - Bexsero approved in Australia
The Australian Therapeutic Goods Administration (TGA) has approved Bexsero, a multi-component Meningococcal B vaccine (MenB) for use in individuals from two months of age and older. Read More >>

Tags: Novartis, Bexsero, MenB, meningococcal, vaccine, approval

5479
Views
A positive review of  Roche’s  Perjeta in early stage breast cancer A positive review of Roche’s Perjeta in early stage breast cancer
The FDA has issued a positive review of Perjeta and recommended accelerating approval. In mid-stage trials, women with early-stage breast cancer who received the drug had significantly fewer tumor Read More >>

Tags: Perjeta, Roche, breast cancer, early stage, FDA, review

2815
Views
ADHD Drug of Shire has failed the depression test ADHD Drug of Shire has failed the depression test
Shire has stopped the development of its ADHD drug. Vyvanse has failed two major, late-stage tests - so it seems to be inappropriate for derpession treatment. Read More >>

Tags: vyvasine, Shire, derpession, ADHD

7199
Views
Novartis’ COPD treatments approved in EU and Japan Novartis’ COPD treatments approved in EU and Japan
Ultibro Breezhaler has been approved by the European Commission as a maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). Ultibro Inhalation Capsul Read More >>

Tags: Ultibro, COPD, drug, Novartis, approval, EU, Japan

2285
Views
Pneumococcal Vaccine PCV7 has proved to be succesfull Pneumococcal Vaccine PCV7 has proved to be succesfull
The results of a new study show a large overall reduction in hospitalizations in the decade following the introduction of PCV7- the 7-valent pneumococcal conjugate vaccine introduced in 2000. Read More >>

Tags: PCV7, pneumococcal vaccine

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013